Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Aprea Therapeutics (NASDAQ:APRE) and maintained a price target of $11.
August 13, 2024 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Aprea Therapeutics and maintained a price target of $11.
The reiteration of an Outperform rating and a maintained price target of $11 by a reputable analyst can boost investor confidence in Aprea Therapeutics, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100